Effects of Intravitreal Aflibercept on the Systemic Insulin‐like Growth Factor‐I and Vascular Endothelial Growth Factor‐A in Patients with Diabetic Retinopathy and Age‐Related Macular Degeneration
Open Access
- 1 January 2021
- journal article
- research article
- Published by Wiley in Journal of Ophthalmology
- Vol. 2021 (1) , 7058505
Abstract
Purpose . To analyze the effect of intravitreal aflibercept injections on systemic levels of insulin‐like growth factor‐1 and vascular endothelial growth factor‐A in patients with diabetic retinopathy and age‐related macular degeneration. Methods . Vascular endothelial growth factor‐A and insulin‐like growth factor‐1 levels were determined before and one week and four weeks after intravitreal injection of aflibercept (2.0 mg/50 μ l) for 19 patients with age‐related macular degeneration (mean age, 76 ± 11 years) and 18 patients with diabetic retinopathy (mean age, 64 ± 14 years). Twenty‐two healthy individuals were enrolled as controls. Results . A significant decline in systemic vascular endothelial growth factor‐A level, from 43 (30–57) pg/ml at baseline to 8 (8–8) pg/ml ( p < 0.001) at week one and 17 (8–25) pg/ml ( p = 0.0054) at week four, was observed in the age‐related macular degeneration group. In the diabetic retinopathy group, vascular endothelial growth factor‐A levels declined from 53 (35–117) pg/ml to 2 (1–5) pg/ml ( p < 0.0001) one week after injection and 16 (13–22) pg/ml four weeks after injection ( p = 0.0327). At baseline, systemic insulin‐like growth factor‐1 concentration was higher in the diabetic retinopathy group (57 [37–99] pg/ml) than in the age‐related macular degeneration group (35 [24–51] pg/ml) ( p = 0.0056). A subgroup analysis showed that patients in the proliferative diabetic retinopathy subgroup had significantly higher systemic insulin‐like growth factor‐1 concentrations (71 [44.7–243] pg/ml) than those in the nonproliferative diabetic retinopathy subgroup (43 [29–66] pg/ml) ( p = 0.0048). Conclusions . The difference between the baseline systemic insulin‐like growth factor‐1 levels of the age‐related macular degeneration and diabetic retinopathy groups and the higher insulin‐like growth factor‐1 levels in the proliferative diabetic retinopathy subgroup one week after aflibercept therapy suggest that insulin‐like growth factor‐1 may play a role in the pathomechanism of diabetic retinopathy.Keywords
This publication has 29 references indexed in Scilit:
- Expression of Neonatal Fc Receptor in the EyeInvestigative Ophthalmology & Visual Science, 2014
- Targeting the Insulin Growth Factor and the Vascular Endothelial Growth Factor Pathways in Ovarian CancerMolecular Cancer Therapeutics, 2012
- Different Populations of Circulating Endothelial Cells in Patients with Age-Related Macular Degeneration: A Novel Insight into PathogenesisInvestigative Ophthalmology & Visual Science, 2011
- Diabetic retinopathyThe Lancet, 2010
- The Natural History and Prognosis of Neovascular Age-Related Macular DegenerationOphthalmology, 2008
- Anti-VEGF Agents in the Treatment of Neovascular Age-related Macular Degeneration: Applying Clinical Trial Results to the Treatment of Everyday PatientsAmerican Journal of Ophthalmology, 2007
- Causes and Prevalence of Visual Impairment Among Adults in the UnitedStatesArchives of Ophthalmology (1950), 2004
- The epidemiology of age-related macular degenerationAmerican Journal of Ophthalmology, 2004
- Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scalesOphthalmology, 2003
- Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects.Journal of Clinical Investigation, 1993